ECE2023 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (159 abstracts)
Oral Semaglutide Improves Metabolic Outcomes in Type 2 Diabetes: A Spain-based Study
Carlos Casado 1 , Jersy Jair Cardenas Salas 1,2 , Roberto Miguel Sierra Poyatos 1,3 , Teresa Montoya Alvarez 2 , Diego Meneses González 1 , Jorge Gabriel Ruiz Sánchez 1 , Bogdana Luiza Luca 1 , Begoña Sánchez Lechuga 1 , María de los Angeles Velez Romero 1 & Clotilde Vazquez Martinez 1,2,3
1Fundación Jiménez Diaz, Endocrinology and Nutrition, Madrid, Spain; 2Hospital Universitario Infanta Elena, Valdemoro, Spain; 3General Hospital Villalba, Collado Villalba, Spain
Objectives: To evaluate the changes in HbA1c, basal glucose, weight, and lipid profile in patients with type 2 diabetes after starting oral semaglutide.
Methods: This study was conducted in Madrid, Fundación Jiménez Díaz, Infanta Elena and General de Villalba hospitals. A total of 75 patients with type 2 diabetes were included. The mean age was 62.0±10.5 years and 60% were men. The mean duration of diabetes was 7.3±6.6 years, and 66.7% had hypertension, 67.6% had dyslipidemia, 14.9% were smokers, 23.0% had sleep apnea, and 26.4% had microvascular disease. Basal treatment included insulin in 12.0%, metformin in 86.7%, SGLT2i in 48%, DPP4i in 41.9%, GLP1-Ra in 1.3%, repaglinide in 8.1%, and Sulphonylurea in 2.7%. A total of 58.3% of patients reached a dose of 7 mg, and 41.7% reached 14 mg. 4 patients discontinued the treatment, 2 due to adverse effects and 2 due to administrative problems. Gastrointestinal adverse effects were reported in 16% of patients. The study had a follow-up period of 7.3±6.6 months. Paired T-Student test for parametric data (α), Wilcoxon test for non-parametric data (β), and McNemar test for proportions (ф) were used for statistical analysis.
Results: The following changes were observed after starting oral semaglutide:
| Comparison | |||
| Basal | 6 months | Differences | |
| Basal glucose (mg/dl) α | 165,0±5,9 | 135,0±5,0 | -30,0 (95%IC: -41,1 a -19,0) ** |
| HbA1c (%) α | 7,85± 0,16 | 6,67±0,14 | -1.18 (95%IC: -1,50 a -0.85)** |
| Weight (kg) α | 95.1±1,5 | 89,8±1,4 | -5,4 (95%IC: -6.4 a – 4,3)** |
| BMI (kg/m2) α | 34.5±0,5 | 32.6±0,5 | -1.9 (95%IC: -2.3 a – 1,6)** |
| Total Cholesterol (mg/dl) α | 171,7±5,5 | 153,7±4,3 | -18,0 (95%IC: -27,8 a – 8,2)** |
| LDL-cholesterol (mg/dl) α | 90,8±4,2 | 79,0±3,8 | -11,8 (95%IC: -18,5 a – 5,1)** |
| Triglycerides (mg/dl) β | 159(P25-75:121-208) | 131(P25-75:102-172) | -24(95%IC: -38 a -4)** |
| HbA1c <7% ф | 33,3% | 67,1% | +34,2% (95%IC: 22,6 a 48,6)** |
| HbA1c reductions by basal HbA1c α | |||
| HbA1c > 7% | -1,3 (95%IC: -1,7 a -0,8)** | ||
| .HbA1c > 8% | -1,6 (95%IC: -2,0 a -1,2)** | ||
| HbA1c > 9% | -1,8 (95%IC: -2,3 a -1,3)** | ||
| ** P<0.01; * P<0.05 | |||
Conclusions: Oral semaglutide was associated with significant improvements in HbA1c, fasting glucose, weight, and lipid profile in patients with type 2 diabetes. The treatment was well tolerated, with a low incidence of adverse effects. The results of this study support the use of oral semaglutide.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more